Skip to main navigation Skip to search Skip to main content

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016

  • Mitchell R. Goldstein
  • , Leonard R Krilov
  • , Jaime Fergie
  • , Christopher S Ambrose
  • , Sally Wade
  • , Amanda Kong
  • , Lance Brannman

Research output: Contribution to journalMeeting abstractpeer-review

Abstract

Background. In 2014, the American Academy of Pediatrics recommended against the use of respiratory syncytial virus (RSV) immunoprophylaxis in infants 29-34 weeks gestational age (wGA) at birth without chronic lung disease/bronchopulmonary dysplasia (CLD/BPD) or congenital heart disease (CHD). To inform discussions of the clinical and economic value of RSV immunoprophylaxis in these infants, we compared RSV hospitalization (RSVH) severity and costs incurred by infants hospitalized from 2014-2016 at
Original languageAmerican English
Pages (from-to)S264-S264
JournalOpen Forum Infectious Diseases
Volume5
Issue numbersuppl_1
DOIs
StatePublished - Nov 26 2018

Disciplines

  • Pediatrics
  • Critical Care
  • Medicine and Health Sciences

Cite this